BACKGROUND: Combination antiretroviral therapy (cART) has improved the survival of patients with HIV/AIDS but its impact remains uncertain on the changing prevalence and incidence of neurologic disorders with ensuing effects on mortality. METHODS: The prevalence and incidence of neurologic disorders were examined in patients receiving active care in a regional HIV care program from 1998 to 2008. The mortality hazard ratio (HR) was calculated by Cox proportional hazard models with adjustment for demographic and clinical variables. RESULTS: Of 1,651 HIV-infected patients assessed, 404 (24.5%) were identified as having one or more neurologic disorders, while 41% of AIDS-affected persons exhibited neurologic disease. Symptomatic distal sensory polyneuropathy (DSP, 10.0%) and HIV-associated neurocognitive disorder (HAND, 6.2%) represented the most prevalent disorders among 53 recognized neurologic disorders. Patients with at least one neurologic disorder exhibited higher mortality rates (17.6% vs 8.0%, p < 0.0001), particularly AIDS-related deaths (9.7% vs 3.2%, p < 0.0001), compared with those without neurologic disorders. The highest mortality HR was associated with opportunistic infections of CNS (HR 5.3, 95% confidence interval [CI] 2.5-11.2), followed by HAND (HR 3.1, 95% CI 1.8-5.3) and the presence of any neurologic disorder (HR 2.0, 95% CI 1.2-3.2). The risk of AIDS-related death with a neurologic disorder was increased by 13.3% per 100 cells/mm(3) decrement in blood CD4+ T-cell levels or by 39% per 10-fold increment in plasma viral load. CONCLUSIONS: The burden and type of HIV-related neurologic disease have evolved over the past decade and despite the availability of cART, neurologic disorders occur frequently and predict an increased risk of death.
BACKGROUND: Combination antiretroviral therapy (cART) has improved the survival of patients with HIV/AIDS but its impact remains uncertain on the changing prevalence and incidence of neurologic disorders with ensuing effects on mortality. METHODS: The prevalence and incidence of neurologic disorders were examined in patients receiving active care in a regional HIV care program from 1998 to 2008. The mortality hazard ratio (HR) was calculated by Cox proportional hazard models with adjustment for demographic and clinical variables. RESULTS: Of 1,651 HIV-infectedpatients assessed, 404 (24.5%) were identified as having one or more neurologic disorders, while 41% of AIDS-affected persons exhibited neurologic disease. Symptomatic distal sensory polyneuropathy (DSP, 10.0%) and HIV-associated neurocognitive disorder (HAND, 6.2%) represented the most prevalent disorders among 53 recognized neurologic disorders. Patients with at least one neurologic disorder exhibited higher mortality rates (17.6% vs 8.0%, p < 0.0001), particularly AIDS-related deaths (9.7% vs 3.2%, p < 0.0001), compared with those without neurologic disorders. The highest mortality HR was associated with opportunistic infections of CNS (HR 5.3, 95% confidence interval [CI] 2.5-11.2), followed by HAND (HR 3.1, 95% CI 1.8-5.3) and the presence of any neurologic disorder (HR 2.0, 95% CI 1.2-3.2). The risk of AIDS-related death with a neurologic disorder was increased by 13.3% per 100 cells/mm(3) decrement in blood CD4+ T-cell levels or by 39% per 10-fold increment in plasma viral load. CONCLUSIONS: The burden and type of HIV-related neurologic disease have evolved over the past decade and despite the availability of cART, neurologic disorders occur frequently and predict an increased risk of death.
Authors: Jacqueline A Pettersen; Gareth Jones; Catherine Worthington; Hartmut B Krentz; Oliver T Keppler; Ahmet Hoke; M John Gill; Christopher Power Journal: Ann Neurol Date: 2006-05 Impact factor: 10.422
Authors: Kenneth A Lichtenstein; Carl Armon; Anna Baron; Anne C Moorman; Kathleen C Wood; Scott D Holmberg Journal: Clin Infect Dis Date: 2004-12-06 Impact factor: 9.079
Authors: E A Childs; R H Lyles; O A Selnes; B Chen; E N Miller; B A Cohen; J T Becker; J Mellors; J C McArthur Journal: Neurology Date: 1999-02 Impact factor: 9.910
Authors: Eugene L Asahchop; William G Branton; Anand Krishnan; Patricia A Chen; Dong Yang; Linglong Kong; Douglas W Zochodne; Bruce J Brew; M John Gill; Christopher Power Journal: JCI Insight Date: 2018-12-06
Authors: J Robert Chang; Ruma Mukerjee; Asen Bagashev; Luis Del Valle; Tinatin Chabrashvili; Brian J Hawkins; Johnny J He; Bassel E Sawaya Journal: J Biol Chem Date: 2011-09-28 Impact factor: 5.157
Authors: Jennifer E Iudicello; Emily J Kellogg; Erica Weber; Christine Smith; Igor Grant; Daniel L Drane; Steven Paul Woods Journal: J Neuropsychiatry Clin Neurosci Date: 2012 Impact factor: 2.198
Authors: Veera Venkata Ratnam Bandaru; Michelle M Mielke; Ned Sacktor; Justin C McArthur; Igor Grant; Scott Letendre; Linda Chang; Valerie Wojna; Carlos Pardo; Peter Calabresi; Sody Munsaka; Norman J Haughey Journal: Neurology Date: 2013-09-11 Impact factor: 9.910
Authors: Weston C Roda; Michael Y Li; Michael S Akinwumi; Eugene L Asahchop; Benjamin B Gelman; Kenneth W Witwer; Christopher Power Journal: J Neurovirol Date: 2017-05-16 Impact factor: 2.643
Authors: Quynh T Vo; Christopher Cox; Xiuhong Li; Lisa P Jacobson; Rosemary McKaig; Ned Sacktor; Ola A Selnes; Eileen Martin; James T Becker; Eric N Miller Journal: J Neurovirol Date: 2012-12-11 Impact factor: 2.643